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Clinicopathologic Features of Metachronous or
Synchronous Gastric Cancer Patients with Three or More
Primary Sites
Introduction
Since 2002, a population-based mass-screening program for
gastric cancer was started by the Ministry of Health and Welfare in
Korea, resulting in increasing numbers of patients with early gastric
cancer. With the increased detection of early gastric cancer and the
improvement of surgical procedure during the past three decades (1-3),
gastric cancer survival has improved. Long-term follow-up for re-
currence has led to an increased incidence of second primary cancers
(4,5). 
Multiple primary cancers (MPC) in one patient has been a frequent
finding in recent decades. Although the mechanism for the pathogenesis
of MPC has yet to be clarified, some factors such as heredity, con-
stitution, environment, immunology, carcinogens including viruses,
radiotherapy, and chemical treatments have been implicated. Increa-
singly elderly patient populations and improved diagnostic techniques
have also been indicated as possible causes (6). Among patients
with MPC, triple cancers are known to occur in 0.5%, and quadruple
or quintuple cancers in less than 0.1% of the population (7). In Western
Europe and the U.S., a number of cohort studies have examined the
risk of a second neoplasm after the diagnosis of a specific tumor (8-10).
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Purpose
We investigated the clinicopathologic information of patients with gastric cancer with multiple
primary cancers (GC-MPC) of three or more sites.
Materials and Methods
Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital,
Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites
were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the
clinical data and overall survival using the medical records of these 41 GC-MPC patients. We
defined synchronous cancers as those occurring within 6 months of the first primary cancer,
while metachronous cancers were defined as those occurring more than 6 months later.
Results
Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than
patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous
GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for
synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous
GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with
median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall
survival rates of 48.2%and 80.7%, respectively (p＜0.001).
Conclusion
Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early
detection of additional primary malignancies will enable proper management with curative
intent.
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│ http://www.e-crt.org│However, there are few reports of MPC for gastric cancer. This is
because gastric cancer is less frequent in Western Europe and the
U.S. than it is in East Asia. In addition, multiple primary cancers of
three or more sites are extremely rare conditions in patients with
gastric cancer. Therefore, there is little data which reports the inci-
dence and clinical features of this rare disease entity.
Therefore, we performed this study to evaluate the incidence of
gastric cancer patients with three or more primary cancers. In addition,
we also investigated clinicopathologic information of metachronous
and synchronous gastric cancer patients in order to improve patient
management and follow-up.
Materials and Methods
1 Patients
Between January 1995 and December 2009, 105,908 patients
were diagnosed with malignancy at Severance Hospital, Yonsei
University Health System. Among these, 113 (0.1%) patients with
MPC of three or more sites were registered, and 41 (36.3%) of these
had synchronous or metachronous gastric cancer. Diagnosis of gastric
cancer and other MPC were pathologically confirmed in all patients.
2 Methods 
We retrospectively reviewed clinicopathologic features of these
41 patients with metachronous or synchronous gastric cancer in MPC
of three or more sites. The following data was collected; gender, age
at initial cancer diagnosis, stage, gastric cancer histology, and survival
from the time of first diagnosis of cancer. The tumor stage of the
gastric cancer was determined according to Tumor-Node-Metastasis
(TNM) classification (American Joint Committee on Cancer, 6th
edition). Two main categories were used for histological typing:
differentiated type (including papillary adenocarcinoma and well and
moderately differentiated tubular adenocarcinoma) and undiffe-
rentiated type (including poorly differentiated tubular adenocarcinoma,
mucinous adenocarcinoma, and signet ring cell adenocarcinoma).  
The MPC was defined according to Warren and Gates’s criteria
(11). The definition of MPC was as follows: 1) the tumor had to
have definite features of malignancy, 2) the tumor had to be separate
and distinct from the index tumor, which was gastric adenocarcinoma
in this study, 3) the possibility of the tumor being a metastasis of the
index tumor had to be ruled out. Based on this definition, we selected
a total of 113 patients with three or more primary cancers between
1995 and 2009. Then, we selected 41 patients who were diagnosed
with primary gastric cancer, synchronously or metachronously. 
In terms of the chronicity, we defined synchronous and metach-
ronous cancer based on Moertel’s definition. Synchronous cancers
were defined as those occurring within 6 months of the first primary
cancer, while metachronous cancers were defined as those occurring
more than 6 months later (12). Overall survival was defined as the
time from first primary cancer diagnosis to death (of any cause).
3 Statistics
For statistical analysis, we used the χ
2-test and Fisher’s exact test
for categorical variables and the student’s t-test for continuous
variables. The survival curve was calculated using the Kaplan-Meier
method and the statistical difference in prognosis was analyzed
using a log rank test. SPSS ver. 17.0 (SPSS Inc., Chicago, IL) was
used throughout and p-values of ＜0.05 were considered significant.
Results
1 Clinicopathologic features of synchronous and me-
tachronous MPC
A total of 41 gastric cancer patients were diagnosed with three or
more primary sites (GC-MPC). Among these, 34 (82.9%) had triple, 6
(14.6%) had quadruple and 1 (2.4%) had quintuple primary mali-
gnancies. Seventeen patients (41.5%) were diagnosed with MPC
synchronously, whereas 24 (58.5%) were diagnosed metachronously.
Among 17 patients with synchronous GC-MPC, 6 patients were
diagnosed with other malignancies before gastric cancer. In addition,
8 of 17 patients had 1 simultaneous malignancy in addition to
gastric cancer, and 8 other patients had 2. Furthermore, one patient
was diagnosed simultaneously with 3 other malignancies (esophagus,
rectum, small bowel). Meanwhile, of 24 patients diagnosed with
metachronous GC-MPC, 13 patients developed other malignancies
after gastric cancer and 11 had other malignancies before gastric
cancer.
Clinicopathologic data for synchronous and metachronous GC-
MPC patients are described in Table 1. Twenty-nine (70.7%) patients
were male, and the median age was 59 years (range, 27 to 79 years).
The median time interval between the first cancer and the second
cancer was 42 months (range, 11.5 to 225.2 months) and the time
interval between the second and third cancer was 43 months (range,
7.7 to 133.3 months). Of the 39 evaluable patients, the TNM stage
of the gastric cancer was early stage (I or II) in 34 cases (82.9%) and
advanced stage (III or IV) in 5 cases (12.2%).
Regarding stage, histology, and time interval between each
cancer, there were no differences between the synchronous and
metachronous groups. Patients in the metachronous group had more
female (p=0.003) and younger (p=0.013) patients than those in
synchronous group. The incidence of early-stage and poorly-
differentiated tumor was slightly higher in gastric cancer patients
Cancer Res Treat. 2010;42(4):217-224
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with metachronous GC-MPC than in those with synchronous GC-
MPC (91.7% vs. 70.6% for stage I/II and 54.2% vs. 23.5% for
poorly differentiated histology, respectively). Excluding gastric
cancer, we also analyzed the stages of the other primary cancers. In
the subset analysis, early stage cancers were slightly more frequent
in the synchronous group (25% vs. 42.3%) without statistical
significance (p=0.217).
2 Site distribution of MPC
For a total of 41 patients, the most common site of MPC other
than gastric cancer was colorectal cancer (n=16, 39%), followed by
cancers in the lung (n=10, 24.4%), head & neck (n=10, 24.4%), and
thyroid (n=9, 22%), as shown in Table 2 and Fig. 1A. We also
analyzed site distribution of MPC according to the chronicity.
Among the 17 synchronous gastric cancer patients, other common
primary sites were as follows (Fig. 1B): head & neck (n=8, 47.1%),
esophagus (n=6, 35.3%) and lung (n=4, 23.5%). In contrast, the most
common sites for the 24 metachronous patients were: colorectum
(n=14, 58.3%), thyroid (n=7, 29.2%) and lung (n=6, 25%). By way
of comparison, esophageal cancer and head & neck cancer were
demonstrated more frequently in the synchronous group (35.3% vs.
4.2%, p≤0.001 and 47.1% vs. 8.3%, p=0.008, respectively) while
colorectal cancer was more frequent in the metachronous group
(58.3% vs. 11.8%, p=0.003).
We also analyzed the site distribution of MPC in terms of gender
distribution. Among 41 GC-MPC patients, 29 (70.7%) patients were
male and 12 (29.3%) were female. In males, the most common site
for MPC was the head & neck (n=10, 34.5%), followed by the colo-
rectum (n=9, 31%), lung (n=7, 24.1%), kidney (n=7, 24.1%), and
esophagus (n=6, 20.7%) as shown in Fig. 2A. In females, the most
common site was the colorectum (n=7, 58.3%), followed by the thyroid
(n=4, 33.3%), breast (n=4, 33.3%), and endometrium (n=3, 25%).
Table 2. Site distribution of multiple primary cancers in patients
with synchronous or metachronous gastric cancer
Site Synchronous  Metachronous p-value
GC-MPC*(n=17) GC-MPC (n=24)
Colorectum 2 (11.8) 14 (58.3) 0.003
Esophagus 6 (35.3) 1 (4.2) ＜0.001
Small-bowel 1 (5.9)
Duodenum 2 (11.8)
Liver 3 (17.6) 1 (4.2) NS
�
Bile duct 3 (12.5)
Gallbladder 1 (4.2)
Ampula of vater 1 (5.9)
Lung 4 (23.5) 6 (25) NS
Head & neck 8 (47.1) 2 (8.3) 0.008
Thyroid 2 (11.8) 7 (29.2) NS
Breast 1 (5.9) 3 (12.5) NS
Endometrium 2 (8.3)
Ovary 1 (4.2)
Cervix 1 (4.2)
Kidney 3 (17.6) 4 (16.7) NS
Prostate 2 (11.8) 2 (8.3) NS
Ureter & bladder 2 (11.8) 2 (8.3) NS
Hematologic  1 (5.9) 2 (8.3) NS
cancer
Parentheses indicate percentages. 
*gastric cancer with multiple primary cancer, 
�not significant.
Total (n=41) Synchronous  Metachronous  p-value
GC-MPC*(n=17) GC-MPC (n=24)
Gender (%) 0.003
Male 29 (70.7) 16 (94.1) 13 (54.2)
Female 12 (29.3) 1 (5.9) 11 (45.8)
Age (yr) 0.013
Median (range) 59 (27-79) 62 (53-79) 58 (27-67)
Stage (%) 0.112
I or II 34 (82.9) 12 (70.6) 22 (91.7)
III or IV 5 (12.2) 3 (17.6) 2 (8.3)
Unknown 2 (4.9) 2 (11.8) 0
Differentiation (%) 0.062
Well 24 (58.5) 13 (76.5) 11 (45.8)
Poor 17 (41.5) 4 (23.5) 13 (54.2)
Time interval between primary cancers (mo)
1st-2nd, median (range) 42 (11.5-225.2) 55 (20.3-167.6)
� 63 (11.5-225.2) 0.744
2nd-3rd, median (range) 43 (7.1-133.3) 46 (13.2-126.8)
� 39 (7.1-133.3) 0.616
Table 1. Clinicopathologic data for patients with gastric cancer in multiple primary cancers of more than three sites
*gastric cancer with multiple primary cancer, 
�this time interval indicates the onset duration between two cancers other than synchronous cancers.When categorizing primary cancer sites based on smoking correlation,
male patients demonstrated more frequent smoking related cancers
such as head & neck, lung, kidney, esophagus, bladder cancers than
female patients (n=34, 53.1%vs. n=4, 15.4%, respectively, p=0.002).
Fig. 2B and 2C compare the patients with synchronous primary
cancer and those with metachronous primary cancer with regard to
gender. In the metachronous group, the primary site distribution by
gender was similar to that of the overall distribution (Fig. 2B). Con-
versely, in the synchronous group, the majority of patients were
male and the primary site distribution by gender was different from
the overall distribution (Fig. 2C). The most common sites in des-
cending frequency were: the head & neck, esophagus, lung, liver,
kidney, and colorectum.
3 Survival outcome and cause of death
With a median follow-up duration for the whole group (41 patients)
of 5.6 years (range, 0.1 to 23.2 years), the median overall survival
duration and 10-year overall survival rate were 14.8 years (figure
not shown) and 63.2%, respectively. The same figures for the
synchronous and metachronous GC-MPC groups, respectively,
were 4.7 years and 48.2%, and 14.8 years and 80.7% (p＜0.001)
(Fig. 3). We analyzed overall survival by gender, stage distribution,
and gastric cancer histology. The survival differences between the
synchronous and metachronous GC-MPC groups were significant in
male (p=0.002), stage I/II (p=0.011) and well differentiated
histology (p=0.01) groups, while the difference in female (p=0.629),
stage III/IV (p=0.502) and poorly differentiated histology (p=0.154)
groups did not reach statistical significance (Table 3). 
At the time of the analysis, 13 patients had died of either gastric or
other primary cancers. Of these 13 patients, 8 patients were meta-
chronous and 5 patients were synchronous. The causes of death are
presented in Table 4.
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Discussion
We described the clinicopathologic features of a rare disease
entity, GC-MPC, and analyzed its clinical significances to establish
follow-up plan in cancer patients. During the 15 year investigation
period, 0.1% of cancer patients had a MPC with three or more
primary sites, and 36.3% of these were gastric cancer patients. This
incidence is consistent with previous studies which reported pre-
valences of 0.029 to 1.7% (7,13,14). 
Synchronous and metachronous gastric cancer patients showed
somewhat different second cancer distribution. For metachronous
gastric cancer patients, the most common cancer sites in descending
order were: colorectum, thyroid, lung, kidney and breast. This finding
is similar to the distribution of cancer in the general Korean population
(15): stomach, colorectum, thyroid, breast, liver and lung in descending
order of frequency. However, interestingly, the site distribution for
synchronous gastric cancer demonstrated a different order: head &
neck, esophagus, lung, and kidney. A possible reason for this pheno-
menon may be shared risk factors, especially cigarette smoking.
Smoking is thought to be a risk factor for gastric cancer (16,17). The
gender difference between synchronous and metachronous gastric
cancer also supports this assumption. More male gastric cancer patients
were diagnosed initially with multiple synchronous sites than female
patients. In further subgroup analysis, smoking related cancers (head
& neck, lung, esophagus, kidney, bladder) were significantly more
common in males than in female patients. This suggests that smoking
plays an important role in the increased incidence of synchronous
disease in male patients. More careful examination of these sites
may therefore be needed at the time of diagnosis and during the follow-
up period of the gastric cancer. Further epidemiologic study is
warranted to clarify this point.
In addition, the metachronous gastric cancer group contained
more female and younger cases. These findings seem to be caused
by different peak ages between males and females. According to the
Korean cancer registry (15), there are two peak incidences in females.
Breast and thyroid cancers in females were most frequently diagnosed
in the fourth and fifth decades, whereas other malignancies like
gastric cancer were often found in the seventh decade. Conversely, most
cancers in males were diagnosed in the seventh decade. Therefore,
females were at greater risk of being diagnosed with a first primary
cancer of breast or thyroid cancer at a younger age, and those who
survived their first primary cancer were at greater risk of developing
a metachronous second primary cancer thereafter.
Although there is still little data for the underlying mechanism,
three main explanations have been put forward for MPC. First, with
longer survival, there is a greater likelihood of attack by many carci-
nogens, resulting in the development of more precancerous lesions.
Additionally, assuming the risk of cancer is constant, it is more
likely that precancerous lesions will develop into clinically significant
cancers due to accumulation of genetic changes (6). This mechanism
is explained by multistep carcinogenesis over time and the molecular
and environmental changes of body associated with the aging process.
Second, “field carcinogenesis” may be another mechanism for MPC
0.0
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Fig. 3. Ten year overall survival difference between synchronous and
metachronous gastric cancer with multiple primary cancer (GC-MPC).
Table 3. Difference of 10-year survival rate between synchronous
and metachronous GC-MPC and subgroup analysis
10-year survival  10-year survival   
Site rate of  rate of p-value
synchronous  metachronous
GC-MPC*(n=17) GC-MPC (n=24)
Total patients 48.2 80.7 < 0.001
Male 28.1 81.8 0.01
Female 56 80.2 0.629
Stage
Early (I or II) 37 84.2 0.011
Advanced (III or IV) 50 33.3 0.502
Differentiation
Well 28.1 81.8 0.01
Poor 80.8 33.3 0.154
Values indicate percentages. *gastric cancer with multiple primary cancer.
Table 4. Site distribution of tumors in patients who died of either
gastric or another primary cancer
Site  Synchronous  Metachronous
GC-MPC*(n=17) GC-MPC (n=24)
Stomach 4 (50)
Colorectum 1 (25)
Liver 1 (12.5) 1 (25)
Bile duct 2 (50)
Lung 1 (12.5)
Head & neck 1 (12.5)
Hematologic cancer 1 (12.5) 1 (25)
Total 8 (100) 5 (100)
Parentheses indicate percentages. *gastric cancer with multiple primary cancer.Joo Hoon Kim, et al_Clinical Characteristics of Gastric Cancer Patients with Multiple Primary Cancers
pathogenesis (12,18,19). This theory implies that if cells in a similar
microenvironment or with similarly susceptible cell biology are
exposed to the same dose of carcinogens for the same duration of
time, they have a similar risk of developing into cancer (20). The
association of upper aerodigestive tract cancer and lung cancer is a
well studied example of the field carcinogenesis theory (21,22). Lastly,
genetic vulnerability due to specific genetic mutations may be res-
ponsible. MLH1, MSH2, MSH6, PMS1, and PMS2 mutations in
hereditary nonpolyposis colorectal cancer have been known to
increase the genetic susceptibility for uterus, ovary, and stomach
cancer (23).
The survival outcome in our study is consistent with previous
studies (24,25), which suggests that metachronous patients have
better prognoses than synchronous patients. In this study, the pro-
portion of early stage (I or II) gastric cancer was 82.9%. Although
recent developments in diagnosis and the introduction of mass
screening programs have allowed increased detection of early
gastric cancer, the proportion of early gastric cancer in this study is
much higher than in the general population of Korea (50%). As
patients with histories of cancer tend to undergo regular medical
check-ups, this could lead to earlier diagnoses of new malignancies
at curable stages (6). For these reasons, multiplicity of primary
malignancies does not always imply a poor prognosis. Furthermore,
metachronous status may sometimes result in a better survival outcome
due to the detection of second or third primary cancer at earlier stages.
Also, the better survival in the metachronous GC-MPC was maintained
even when we did not include the favorable prognostic cancers such
as thyroid or prostate cancer (data not shown).
Although our study had some unique findings, there were two
potential limitations. First, the retrospective single center nature of
our study may limit the generalization of our results. However, our
analysis is based on data from the registry of the Yonsei Cancer
Center, a major, 2000-bed tertiary hospital in Korea. This well
organized and standardized tumor registry has records for every case of
carcinoma in situ or carcinoma in our hospital since 1980. Therefore,
the data from our registry can be interpreted as being broadly repre-
sentative of Korea as a whole. Secondly, because of the long follow-
up duration, some information was insufficient, and altered diagnostic
and treatment strategies may have influenced the results. Therefore,
further validation with nationwide data is needed, and this information
might be useful in the establishment of a national diagnostic/treatment
strategy for gastric cancer patients.
Conclusion
We reported the clinical features of multiple primary cancer in
gastric cancer patients. To our knowledge, this is the first study des-
cribing the clinical features and prognosis of three or more primary
sites in gastric cancer. The early detection of additional primary
malignancies will enable prompt management with curative intent.
Therefore, based on our results, further genetic and epidemiologic
studies are warranted to clarify understanding of the pathogenesis
and improve therapeutic outcome.
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